Please login to the form below

Not currently logged in
Email:
Password:

Europe, US and Australia announce joint drug inspections

The US HHS has announced a new international initiative to enhance drug safety

The US Health and Human Services Department (HHS) has announced a new international initiative to enhance drug safety.

The Food and Drug Administration (FDA) will undertake the initiative, currently in the pilot stage, with its counterparts in Europe and Australia. Initially, the project will focus on makers of active pharmaceutical ingredients, concentrating on countries such as China and India, who produce a significant volume of the world's pharmaceutical raw materials.

Aiming to reduce duplication and to identify problems quickly, the authorities would share inspection schedules, results and other information.

"These programs will significantly increase our collaboration with international and private sector partners to enhance the safety of imported food and medical products," said HSS Secretary Mike Leavitt. "Working together, we intend to offer expedited access to those products shown to meet our standards and to focus more of our resources on those products that present higher risks."

In February 2008, Baxter International recalled it blood-thinning drug Heparin after a number of serious adverse reactions were reported. An investigation by the FDA identified a contaminant in the drug. These tighter inspections together with the sharing of information between authorities are a huge leap towards preventing a similar occurrence in the future.

10th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics